Cooper Companies presents a distinctive valuation profile within the medical devices sector, trading at a P/E ratio of 59.11 while generating modest profitability metrics that systematic screening flags for closer examination. The company's current price of $72.32 sits substantially below its 52-week high of $89.83, representing approximately 19% downside from recent peaks against a market capitalization of $14.1 billion.

The fundamental picture reveals several operational strengths. Revenue growth of 6.09% year-over-year demonstrates consistent top-line expansion in the competitive vision care and women's health markets. The company maintains a robust gross margin of 65.55%, indicating pricing power and operational efficiency in manufacturing. Conservative balance sheet management appears evident through a debt-to-equity ratio of just 0.30 and a current ratio of 1.89, positioning the firm with adequate liquidity buffers.

Material headwinds emerge when examining profitability trends. The screener highlights a sharp EPS decline of 42.61% year-over-year, contrasting with positive revenue momentum and suggesting margin compression or elevated expenses. Returns metrics remain subdued, with ROE at 2.84% and operating margins of 11.77%, both modest relative to the premium valuation multiple. The elevated P/E ratio relative to near-term earnings power creates sensitivity to further profit deterioration.

Research perspective indicates COO's beta of 0.82 positions the stock as moderately defensive within healthcare allocations. Relative to specialized peers in ophthalmology and fertility solutions, Cooper's scale and diversified product portfolio across contact lenses and women's health devices offers differentiated exposure, though current profitability metrics warrant continued monitoring against the prevailing valuation framework.